L3VLUP
ProSign in

MDLN · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MDLNVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MDLN
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterMDLNVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 2021none listed holders, n.a.35 holders, $10.1bn
Q4 2021none listed holders, n.a.28 holders, $12.4bn
Q1 2022none listed holders, n.a.23 holders, $16.1bn
Q2 2022none listed holders, n.a.25 holders, $18.1bn
Q3 2022none listed holders, n.a.22 holders, $18.4bn
Q4 2022none listed holders, n.a.28 holders, $18.4bn
Q1 2023none listed holders, n.a.26 holders, $21.4bn
Q2 2023none listed holders, n.a.27 holders, $24.7bn
Q3 2023none listed holders, n.a.33 holders, $24.3bn
Q4 2023none listed holders, n.a.32 holders, $28.6bn
Q1 2024none listed holders, n.a.31 holders, $29.8bn
Q2 2024none listed holders, n.a.29 holders, $33.4bn
Q3 2024none listed holders, n.a.27 holders, $33.5bn
Q4 2024none listed holders, n.a.26 holders, $28.5bn
Q1 2025none listed holders, n.a.21 holders, $35.4bn
Q2 2025none listed holders, n.a.21 holders, $32.3bn
Q3 2025none listed holders, n.a.22 holders, $25.9bn
Q4 202528 holders, $5.5bn26 holders, $31.8bn
Q1 202628 holders, $7.9bn25 holders, $31.8bn
Q2 202621 holders, $9.1bn26 holders, $34.6bn
MDLN

Medline Inc

New listing

Holders
28
Reported value
$5.5bn
Buyers
39
Sellers
0

Not ranked this quarter: its new positions are allocations in a new listing.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 43 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MDLN (17)

Artisan Partners LP, D1 Capital Partners LP, Davidson Kempner Capital Management LP, Dragoneer Investment Group LLC, Durable Capital Partners LP, ExodusPoint Capital Management LP, Farallon Capital Management LLC, Freestone Grove Partners LP, Holocene Advisors LP, Lone Pine Capital LLC, Maverick Capital Ltd, Schonfeld Strategic Advisors LLC, Soros Fund Management LLC, Tudor Investment Corp, Verition Fund Management LLC, Viking Global Investors LP, Walleye Capital LLC

Only VRTX (15)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Two Sigma Advisers LP, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →